ArticleInfection2026
Lower hepatitis E clearance rates in thoracic organ recipients compared to visceral organ recipients: an effect of stronger immunosuppression?
Article in Infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsHepatitis E virus (HEV) infection is a significant concern for solid organ transplant (SOT) recipients. However, the extent of this disease among recipients of different organs remains unclear.
methodsThis retrospective cohort study reviewed 63 adult SOT patients with PCR-confirmed HEV infection, including liver, kidney, heart, and lung transplant recipients.
resultsChronic HEV infection (viral persistence beyond three months) was observed in 64% of infected patients, with a significantly higher occurrence in thoracic organ recipients compared to abdominal organ recipients. Ribavirin therapy, started in 40 patients with chronic infection, resulted in a sustained virological response in 78%. However, thoracic organ recipients exhibited notably lower clearance rates (55%) than abdominal organ recipients (91%). The use of tacrolimus, cyclosporine A, mycophenolate mofetil, azathioprine, or steroids was not linked to the development or eventual clearance of chronic infection. Nonetheless, 4 out of 25 patients (16%) receiving everolimus cleared the infection. spontaneously, compared to 20 of 39 patients (51%) on regimens without everolimus (p = 0.007). Low-dose maintenance ribavirin therapy proved effective in stabilizing liver function and, in some cases, achieving viral clearance. Despite treatment, four patients with chronic HEV infection died from cirrhosis.
conclusionThis study emphasizes the need for customized treatment Strategies for HEV infection in SOT recipients, highlighting the limitations of serology, the variable response depending on transplant type, and the potential role of long-term ribavirin therapy.
Indexed as
Identifiers
42579071What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.